Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates

A clinical phase I study

Theresa A. Shapiro, Jed W. Fahey, Albena T. Dinkova-Kostova, W. David Holtzclaw, Katherine K. Stephenson, Kristina L. Wade, Lingxiang Ye, Paul Talalay

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

Broccoli sprouts are widely consumed in many parts of the world. There have been no reported concerns with respect to their tolerance and safety in humans. A formal phase I study of safety, tolerance, and pharmacokinetics appeared justified because these sprouts are being used as vehicles for the delivery of the glucosinolate glucoraphanin and its cognate isothiocyanate sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)butane] in clinical trials. Such trials have been designed to evaluate protective efficacy against development of neoplastic and other diseases. A placebo-controlled, double-blind, randomized clinical study of sprout extracts containing either glucosinolates (principally glucoraphanin, the precursor of sulforaphane) or isothiocyanates (principally sulforaphane) was conducted on healthy volunteers who were in-patients on our clinical research unit. The subjects were studied in three cohorts, each comprising three treated individuals and one placebo recipient. Following a 5-day acclimatization period on a crucifer-free diet, the broccoli sprout extracts were administered orally at 8-h intervals for 7 days (21 doses), and the subjects were monitored during this period and for 3 days after the last treatment. Doses were 25 μmol of glucosinolate (cohort A), 100 μmol of glucosinolate (cohort B), or 25 μmol of isothiocyanate (cohort C). The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 ± 8.6% and 19.6 ± 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 ± 2.0% of dose). Thirty-two types of hematology or chemistry tests were done before, during, and after the treatment period. Indicators of liver (transaminases) and thyroid [thyroid-stimulating hormone, total triiodothyronine (T3), and free thyroxine (T4)] function were examined in detail. No significant or consistent subjective or objective abnormal events (toxicities) associated with any of the sprout extract ingestions were observed.

Original languageEnglish
Pages (from-to)53-62
Number of pages10
JournalNutrition and Cancer
Volume55
Issue number1
DOIs
Publication statusPublished - 5 Oct 2006

Fingerprint

Isothiocyanates
Glucosinolates
sprouts (food)
Brassica
isothiocyanates
broccoli
glucosinolates
Safety
metabolism
glucoraphanin
dosage
triiodothyronine
Placebos
placebos
clinical trials
extracts
Acclimatization
Triiodothyronine
Hematology
Thyrotropin

Cite this

Shapiro, Theresa A. ; Fahey, Jed W. ; Dinkova-Kostova, Albena T. ; Holtzclaw, W. David ; Stephenson, Katherine K. ; Wade, Kristina L. ; Ye, Lingxiang ; Talalay, Paul. / Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates : A clinical phase I study. In: Nutrition and Cancer. 2006 ; Vol. 55, No. 1. pp. 53-62.
@article{eff0ed9ea2914cd19d670275651cd95b,
title = "Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: A clinical phase I study",
abstract = "Broccoli sprouts are widely consumed in many parts of the world. There have been no reported concerns with respect to their tolerance and safety in humans. A formal phase I study of safety, tolerance, and pharmacokinetics appeared justified because these sprouts are being used as vehicles for the delivery of the glucosinolate glucoraphanin and its cognate isothiocyanate sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)butane] in clinical trials. Such trials have been designed to evaluate protective efficacy against development of neoplastic and other diseases. A placebo-controlled, double-blind, randomized clinical study of sprout extracts containing either glucosinolates (principally glucoraphanin, the precursor of sulforaphane) or isothiocyanates (principally sulforaphane) was conducted on healthy volunteers who were in-patients on our clinical research unit. The subjects were studied in three cohorts, each comprising three treated individuals and one placebo recipient. Following a 5-day acclimatization period on a crucifer-free diet, the broccoli sprout extracts were administered orally at 8-h intervals for 7 days (21 doses), and the subjects were monitored during this period and for 3 days after the last treatment. Doses were 25 μmol of glucosinolate (cohort A), 100 μmol of glucosinolate (cohort B), or 25 μmol of isothiocyanate (cohort C). The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 ± 8.6{\%} and 19.6 ± 11.7{\%} of dose, respectively) and very much higher and more consistent in cohort C (70.6 ± 2.0{\%} of dose). Thirty-two types of hematology or chemistry tests were done before, during, and after the treatment period. Indicators of liver (transaminases) and thyroid [thyroid-stimulating hormone, total triiodothyronine (T3), and free thyroxine (T4)] function were examined in detail. No significant or consistent subjective or objective abnormal events (toxicities) associated with any of the sprout extract ingestions were observed.",
author = "Shapiro, {Theresa A.} and Fahey, {Jed W.} and Dinkova-Kostova, {Albena T.} and Holtzclaw, {W. David} and Stephenson, {Katherine K.} and Wade, {Kristina L.} and Lingxiang Ye and Paul Talalay",
year = "2006",
month = "10",
day = "5",
doi = "10.1207/s15327914nc5501_7",
language = "English",
volume = "55",
pages = "53--62",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Taylor & Francis",
number = "1",

}

Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates : A clinical phase I study. / Shapiro, Theresa A.; Fahey, Jed W.; Dinkova-Kostova, Albena T.; Holtzclaw, W. David; Stephenson, Katherine K.; Wade, Kristina L.; Ye, Lingxiang; Talalay, Paul.

In: Nutrition and Cancer, Vol. 55, No. 1, 05.10.2006, p. 53-62.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates

T2 - A clinical phase I study

AU - Shapiro, Theresa A.

AU - Fahey, Jed W.

AU - Dinkova-Kostova, Albena T.

AU - Holtzclaw, W. David

AU - Stephenson, Katherine K.

AU - Wade, Kristina L.

AU - Ye, Lingxiang

AU - Talalay, Paul

PY - 2006/10/5

Y1 - 2006/10/5

N2 - Broccoli sprouts are widely consumed in many parts of the world. There have been no reported concerns with respect to their tolerance and safety in humans. A formal phase I study of safety, tolerance, and pharmacokinetics appeared justified because these sprouts are being used as vehicles for the delivery of the glucosinolate glucoraphanin and its cognate isothiocyanate sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)butane] in clinical trials. Such trials have been designed to evaluate protective efficacy against development of neoplastic and other diseases. A placebo-controlled, double-blind, randomized clinical study of sprout extracts containing either glucosinolates (principally glucoraphanin, the precursor of sulforaphane) or isothiocyanates (principally sulforaphane) was conducted on healthy volunteers who were in-patients on our clinical research unit. The subjects were studied in three cohorts, each comprising three treated individuals and one placebo recipient. Following a 5-day acclimatization period on a crucifer-free diet, the broccoli sprout extracts were administered orally at 8-h intervals for 7 days (21 doses), and the subjects were monitored during this period and for 3 days after the last treatment. Doses were 25 μmol of glucosinolate (cohort A), 100 μmol of glucosinolate (cohort B), or 25 μmol of isothiocyanate (cohort C). The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 ± 8.6% and 19.6 ± 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 ± 2.0% of dose). Thirty-two types of hematology or chemistry tests were done before, during, and after the treatment period. Indicators of liver (transaminases) and thyroid [thyroid-stimulating hormone, total triiodothyronine (T3), and free thyroxine (T4)] function were examined in detail. No significant or consistent subjective or objective abnormal events (toxicities) associated with any of the sprout extract ingestions were observed.

AB - Broccoli sprouts are widely consumed in many parts of the world. There have been no reported concerns with respect to their tolerance and safety in humans. A formal phase I study of safety, tolerance, and pharmacokinetics appeared justified because these sprouts are being used as vehicles for the delivery of the glucosinolate glucoraphanin and its cognate isothiocyanate sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)butane] in clinical trials. Such trials have been designed to evaluate protective efficacy against development of neoplastic and other diseases. A placebo-controlled, double-blind, randomized clinical study of sprout extracts containing either glucosinolates (principally glucoraphanin, the precursor of sulforaphane) or isothiocyanates (principally sulforaphane) was conducted on healthy volunteers who were in-patients on our clinical research unit. The subjects were studied in three cohorts, each comprising three treated individuals and one placebo recipient. Following a 5-day acclimatization period on a crucifer-free diet, the broccoli sprout extracts were administered orally at 8-h intervals for 7 days (21 doses), and the subjects were monitored during this period and for 3 days after the last treatment. Doses were 25 μmol of glucosinolate (cohort A), 100 μmol of glucosinolate (cohort B), or 25 μmol of isothiocyanate (cohort C). The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 ± 8.6% and 19.6 ± 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 ± 2.0% of dose). Thirty-two types of hematology or chemistry tests were done before, during, and after the treatment period. Indicators of liver (transaminases) and thyroid [thyroid-stimulating hormone, total triiodothyronine (T3), and free thyroxine (T4)] function were examined in detail. No significant or consistent subjective or objective abnormal events (toxicities) associated with any of the sprout extract ingestions were observed.

UR - http://www.scopus.com/inward/record.url?scp=33749165612&partnerID=8YFLogxK

U2 - 10.1207/s15327914nc5501_7

DO - 10.1207/s15327914nc5501_7

M3 - Article

VL - 55

SP - 53

EP - 62

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 1

ER -